Ran Klein1, Emmanuelle S Ametepe2, Yeung Yam3, Girish Dwivedi3, Benjamin J Chow3. 1. Division of Nuclear Medicine, The Ottawa hospital, 1053 Carling Ave, Ottawa, ON, Canada, Canada, K1Y 4E9 rklein@toh.on.ca. 2. Faculty of Science, University of Ottawa, Ottawa, ON, Canada. 3. Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, Canada K1Y 4W7.
Abstract
AIMS: To determine the influence of cardiac motion on measurements of left ventricular (LV) mass obtained with 64-slice computed tomography (CT) and to elucidate the prognostic value of LV mass on major adverse cardiac events (MACE) and all-cause mortality. Increased LV mass has been linked with MACE. Although Cardiac CT allows measurement of LV anatomy, it is susceptible to motion artefacts often requiring image acquisition during diastasis. There is a need to understand variability in LV mass measurements across phases of the cardiac cycle, and whether mid-diastolic measurements have prognostic value. METHODS AND RESULTS: The study comprised two equally sized cohorts of patients that had undergone retrospectively gated cardiac CT: patients who had MACE and/or all-cause death at follow-up and a matched (age, sex, and risk factors) event-free cohort. LV mass was measured at mid-diastole, end-diastole, and end-systole. Correlation and agreement between phases were determined. The incremental value of mid-diastolic hypertrophy (LVH) over the National Cholesterol Education Programme (NCEP) risk was performed for LV mass indices normalized to body surface area (LVMIBSA) or weight (LVMIWeight). Of 166 patients, 31.3% experienced MACE and 28.9% died of any cause (follow-up 22.9 ± 13.4 months). LV mass at all cardiac phases were strongly correlated (r > 0.94). Mean mid-diastolic LVMIBSA was higher in the cohort with events (93.7 vs. 80.7 g/m2, P= 0.008) as was LVMIWeight (2.26 vs. 1.88 g/kg, P = 0.001). LVMIBSA and LVMIWeight had prognostic value incremental to NCEP with 1.85 and 2.47 hazard ratios, respectively. CONCLUSIONS: Measurement of LV mass can be obtained by cardiac CT images obtained at mid-diastasis. LV mass measurements obtained at mid-diastasis have prognostic value. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To determine the influence of cardiac motion on measurements of left ventricular (LV) mass obtained with 64-slice computed tomography (CT) and to elucidate the prognostic value of LV mass on major adverse cardiac events (MACE) and all-cause mortality. Increased LV mass has been linked with MACE. Although Cardiac CT allows measurement of LV anatomy, it is susceptible to motion artefacts often requiring image acquisition during diastasis. There is a need to understand variability in LV mass measurements across phases of the cardiac cycle, and whether mid-diastolic measurements have prognostic value. METHODS AND RESULTS: The study comprised two equally sized cohorts of patients that had undergone retrospectively gated cardiac CT: patients who had MACE and/or all-cause death at follow-up and a matched (age, sex, and risk factors) event-free cohort. LV mass was measured at mid-diastole, end-diastole, and end-systole. Correlation and agreement between phases were determined. The incremental value of mid-diastolic hypertrophy (LVH) over the National Cholesterol Education Programme (NCEP) risk was performed for LV mass indices normalized to body surface area (LVMIBSA) or weight (LVMIWeight). Of 166 patients, 31.3% experienced MACE and 28.9% died of any cause (follow-up 22.9 ± 13.4 months). LV mass at all cardiac phases were strongly correlated (r > 0.94). Mean mid-diastolic LVMIBSA was higher in the cohort with events (93.7 vs. 80.7 g/m2, P= 0.008) as was LVMIWeight (2.26 vs. 1.88 g/kg, P = 0.001). LVMIBSA and LVMIWeight had prognostic value incremental to NCEP with 1.85 and 2.47 hazard ratios, respectively. CONCLUSIONS: Measurement of LV mass can be obtained by cardiac CT images obtained at mid-diastasis. LV mass measurements obtained at mid-diastasis have prognostic value. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jeroen Walpot; Daniel Juneau; Samia Massalha; Girish Dwivedi; Frank J Rybicki; Benjamin J W Chow; João R Inácio Journal: Radiol Cardiothorac Imaging Date: 2019-12-19
Authors: Wunan Zhou; Meron Teklu; Vy Bui; Grigory A Manyak; Promita Kapoor; Amit K Dey; Alexander V Sorokin; Nidhi Patel; Heather L Teague; Martin P Playford; Julie Erb-Alvarez; Justin A Rodante; Andrew Keel; Sujata M Shanbhag; Li-Yueh Hsu; David A Bluemke; Marcus Y Chen; Marcus Carlsson; Nehal N Mehta Journal: Am J Prev Cardiol Date: 2021-05-30
Authors: Amy E Burchell; Jonathan C L Rodrigues; Max Charalambos; Laura E K Ratcliffe; Emma C Hart; Julian F R Paton; Andreas Baumbach; Nathan E Manghat; Angus K Nightingale Journal: J Clin Hypertens (Greenwich) Date: 2016-10-19 Impact factor: 3.738
Authors: Andrew Lin; Márton Kolossváry; Manish Motwani; Ivana Išgum; Pál Maurovich-Horvat; Piotr J Slomka; Damini Dey Journal: J Cardiovasc Comput Tomogr Date: 2021-03-22
Authors: Tom Kai Ming Wang; Clementina Dugo; Yvonne Gillian; Wynne Yvonne; Semple Heather; Smith Kevin; Cleave Peter; Christiansen Jonathan; To Andrew; Amir Nezar; Tony Scott; Boswell Ross; Gladding Patrick Journal: Med Sci (Basel) Date: 2018-02-15
Authors: Rong Bing; James Henderson; Amanda Hunter; Michelle C Williams; Alastair J Moss; Anoop S V Shah; David A McAllister; Marc R Dweck; David E Newby; Nicholas L Mills; Philip D Adamson Journal: Heart Date: 2019-06-01 Impact factor: 5.994
Authors: Cristobal Rodero; Marina Strocchi; Maciej Marciniak; Stefano Longobardi; John Whitaker; Mark D O'Neill; Karli Gillette; Christoph Augustin; Gernot Plank; Edward J Vigmond; Pablo Lamata; Steven A Niederer Journal: PLoS Comput Biol Date: 2021-04-15 Impact factor: 4.779